Anti-thrombotic efficacy of S007-867: pre-clinical evaluation in experimental models of thrombosis in vivo and in vitro

Misra, Ankita and Prakash, Prem and Aggarwal, Hobby and Dhankani, Priyanka and Kumar, Sachin and Pandey, Chandra P. and Pugh, Nicholas and Bihan, Dominique and Barthwal, Manoj K. and Farndale, Richard W. and Dikshit, Dinesh K. and Dikshit, Madhu (2018) Anti-thrombotic efficacy of S007-867: pre-clinical evaluation in experimental models of thrombosis in vivo and in vitro. Biochemical Pharmacology, 148. pp. 288-297. ISSN 1873-2968

[img]
Preview
Text
Accepted Version
Available under the following license: Creative Commons Attribution Non-commercial No Derivatives.

Download (4MB) | Preview
Official URL: http://dx.doi.org/10.1016/j.bcp.2018.01.013

Abstract

Pharmacological inhibition of platelet collagen interaction is a promising therapeutic strategy to treat intra-vascular thrombosis. S007-867 is a novel synthetic inhibitor of collagen-induced platelet aggregation. It has shown better antithrombotic protection than aspirin and clopidogrel with minimal bleeding tendency in mice. The present study is aimed to systematically investigate the antithrombotic efficacy of S007-867 in comparison to aspirin and clopidogrel in vivo and to delineate its mechanism of action in vitro. Aspirin, clopidogrel, and S007-867 significantly reduced thrombus weight in arterio-venous (AV) shunt model in rats. In mice, following ferric chloride induced thrombosis in either carotid or mesenteric artery; S007-867 significantly prolonged the vessel occlusion time (1.2-fold) and maintained a sustained blood flow velocity for >30 min. Comparatively, clopidogrel showed significant prolongation in TTO (1.3-fold) while aspirin remained ineffective. Both S007-867 and aspirin did not alter bleeding time in either kidney or spleen injury models, and thus maintained hemostasis, while clopidogrel showed significant increase in spleen bleeding time (1.7-fold). The coagulation parameters namely thrombin time, prothrombin time or activated partial thromboplastin time remained unaffected even at high concentration of S007-867 (300 µM), thus implying its antithrombotic effect to be primarily platelet mediated. S007-867 significantly inhibited collagen-mediated platelet adhesion and aggregation in mice ex-vivo. Moreover, when blood was perfused over a highly thrombogenic combination of collagen mimicking peptides like CRP-GFOGER-VWF-III, S007-867 significantly reduced total thrombus volume or ZV50 (53.4 ± 5.7%). Mechanistically, S007-867 (10–300 μM) inhibited collagen-induced ATP release, thromboxane A2 (TxA2) generation, intra-platelet [Ca+2] flux and global tyrosine phosphorylation including PLCγ2. Collectively the present study highlights that S007-867 is a novel synthetic inhibitor of collagen induced platelet activation, that effectively maintains blood flow velocity and delays vascular occlusion. It inhibits thrombogenesis without compromising hemostasis. Therefore, S007-867 may be further developed for the treatment of thrombotic disorders in clinical settings.

Item Type: Journal Article
Keywords: Thrombosis, Anti-thrombotics, Blood flow velocity, Collagen, Hemostasis, Platelet activation
Faculty: ARCHIVED Faculty of Science & Technology (until September 2018)
Depositing User: Dr Nicholas Pugh
Date Deposited: 08 Feb 2018 13:23
Last Modified: 14 Nov 2019 16:09
URI: http://arro.anglia.ac.uk/id/eprint/702608

Actions (login required)

Edit Item Edit Item